Abstract Streptomyces tenebrarius H6 mainly produces three kinds of antibiotics: apramycin, carbamoyltobramycin and some carbamoylkanamycin B. In our present study, a dehydrogenase gene tacB in the tobramycin biosynthetic gene cluster was disrupted by in-frame deletion. The result of TLC bio-autograph analysis demonstrated the disruption mutant strain produced apramycin and a new antibiotic. The new antibiotic was identified as 3Ј-deoxycarbamoylkanamycin C by MS and NMR analysis after isolation and purification. The disruption mutant was restored to produce carbamoyltobramycin in a complementation experiment by the intact tacB gene. Our studies suggested that the tacB gene encodes a 6Ј-dehydrogenase, which reduces the 6Ј-hydroxyl group of paromamine to a keto group, thus facilitating the transfer of an aminogroup to form neamine. This study is the first report on the generation of a tobramycin derivative by gene engineering, and will contribute to clarify the complete biosynthetic pathway of tobramycin.
Introduction
Aminoglycosides are one of the most important antibiotic families applied for clinical purpose. It have a wide antibacterial spectrum and special antibacterial activity against aerobic gram negative bacilli. However its main side-effects as ototoxicity and nephrotoxicity [1] and bacterial drug resistances compromise its clinical usage. This has necessitated the development of structural novel and more potent antibiotics. Based on chemical structure, aminoglycosides can be classified into two major groups: one has an aglycone fully-substituted aminocyclitol which is synthesized from myo-inositol [2] . The other group has a common aglycone of 2-deoxystreptamine (2-DOS). Many important aminoglycosides belong to the second category, such as tobramycin, kanamycin and neomycin.
Compared with other major classes of antibiotics such as macrolides, studies on the biosynthesis of aminoglycosides have fallen behind but in recent years, several gene clusters of 2-deoxystreptamin-containing aminoglycosides have been cloned. Yasumasa Ota et al. [3] first reported the gene cluster of Butirosin, identified the function of BtrC which catalyzes the carbocycle formation from D-glucose-6-phosphate to 2-deoxy-scyllo-inosose (2-DOI) in vivo. And then partial biosynthetic gene clusters of tobramycin, gentamycin, kanamycin, neomycin and ribostamycin were cloned from different strains [4ϳ9] . All these papers proposed the same biosynthetic pathway of 2-DOS, and most genes encoding for enzymes catalyzing each step of 2-DOS biosynthesis have been discovered [3ϳ11]. Finally pseudodisaccharide intermediate paromamine is produced through the addition of dTDP-glucosamine to 2-DOS with the help of glycosyltransferase.
There are several dehydrogenases in the gene cluster of tobramycin, but only the function of TbmA (2-DOI synthase) was demonstrated [4] . In this paper, we explored the function of tacB gene which located in tobramycin biosynthetic gene cluster. Based on gene disruption and complementation experiments, along with the structure analysis of the new antibiotic produced by the tacB disruption mutant, our studies suggest that the tacB gene encodes a 6Ј-dehydrogenase, which catalyzed the 6Ј-hydroxyl group of paromamine to form a keto group. This is the first report on blocking tobramycin derivative biosynthesis due to the ceased expression of a dehydrogenase gene in context with the tacB disruption.
Materials and Methods

General
Methods for isolation and manipulation of DNA were used as described by Sambrook et al. [13] . Transformation of Escherichia coli followed the CaCl 2 method [13] . Conjugation transformation of Streptomyces tenebrarius H6 was performed according to the method described previously [14] . The reference substance 3Ј-deoxycarbamoylkanamycin C (M.W.ϭ511.2) was generated from a mutagenesis strain [16] and purified in our laboratory. Ion-exchange resins were purchased from Shanghai Huazhen Co. Ltd.
Strains, Plasmids and Culture Conditions
Bacterial strains and plasmids used in the study are listed in Table 1 . Agar medium (SM) was used for the S. tenebrarius H6 sporulation [17] and MS [15] for the conjugation between S. tenebrarius H6 and E. coli ET12567 (pUZ8002). Liquid medium (SGGP) was used for S. tenebrarius H6 or mutant strains mycelium growth. For antibiotics production in S. tenebrarius H6 or mutant strains, fermentation was carried out by using seed culture medium and fermentation medium [17] . 2ϫYT medium used in conjugation was prepared as described by Hopwood et al. [15] . If necessary, erythromycin was added at a concentration of 100 mg/ml. E. coli strains were grown in Luria-Bertani (LB) medium at 37°C, supplemented with 50 m g/ml apramycin, 50 m g/ml ampicillin, 25 m g/ml chloromycetin or 25 m g/ml kanamycin when necessary. Bacillus subtilis was incubated in bioassay medium [17] .
Gene Disruption
The recombinant plasmid was constructed for targeted disruption of tacB as follows: A 2.15-kb fragment containing tacB gene was amplified from wild-type S. tenebrarius H6 genomic DNA with primer 1 (CATAAGCTTCAGCCCGAGGACACGC) and primer 3 (GCGCTCTAGATGACCGTCTCCAAGGG). PCR condition was 95°C, 5 minutes for denaturation, 30 cycles of 94°C, 2 minutes, 59°C, 30 seconds, 72°C, 2.5 minutes for extension of DNA. The amplified PCR product was purified, digested with HindIII and XbaI and cloned into the same site of pIJ2925 to yield pSPU501. The SalI-SalI fragment internal to tacB was released and self-ligated as to construct an in-frame disrupted tacB gene named D tacB. And then, the erythromycin-resistant gene (ermE) fragment from plasmid pWHM2 was inserted into the KpnI site. The resulting DtacB-ermE fragment was excised with BglII and cloned into the BamHI site of pHZ132 [18] to create pHZ-D tacB, which was transferred into E. coli ET12567 64 (pUZ8002). Plasmid pHZ-DtacB was introduced into S. tenebrarius H6 by conjugation, which was carried out on MS medium at 28°C for 20 hours. After overlaying with erythromycin (100 m g/ml) and nalidixic acid (50 m g/ml), incubation was continued at 28°C for 7ϳ9 days. Single-crossover exconjugants of S. tenebrarius H6 were obtained using erythromycin as a selective marker. After three rounds of sporulation in the absence of erythromycin, two types of erythromycin-sensitive strains, namely tacB-disruptants and wild-type revertants, were obtained for detection of antibiotic products. To confirm the double-crossover integration of DtacB into the tacB locus, genomic DNA of exconjugant was isolated, and PCR was carried out using primers 1 and 3, the amplification product was subjected to sequencing analysis, and the result was compared with the sequence of tacB in the Genbank.
Complementation of tacB in the Gene Disruption Mutant
To complement the tacB disruption mutant, the intact tacB gene was amplified from the genomic DNA of S. tenebrarius H6 with primer a (GGGACGGTCTAGA-ATGCTGCTGATCTCAG) and primer b (CATAAGCTT-CAGCCCGAGGACACGC). The amplified fragment was cloned between the XbaI and HindIII sites of the expression plasmid pSPU227. The BglII fragment containing PmerϩtacBϩto was inserted into the BamHI site of pIJ2925, and the ermE gene was sub-cloned as a KpnI fragment into the same plasmid. The resulting PmerϩtacBϩtoϩermE fragment was excised with BglII and cloned into the BamHI site of pSET152 [19] , resulting in the final plasmid pSET152-tacB.
pSET152-tacB was introduced into the tacB disrupted mutant strain by conjugation from E. coli ET12567 (pUZ8002).
The erythromycin-resistant (Ery R ) exconjugants were selected for detection of antibiotic products.
Analysis of Antibiotics by TLC and Bio-autography
The fermentation filtrates of the tacB disruption mutants, the tacB complementary colonies (Ery R ) or S. tenebrarius H6 were applied to silica GF 254 TLC glass plate (Huiyou, China), and developed with a solvent system of PrOH : MeOH : ammonia solution (25%)ϭ25 : 20 : 23 at 37°C for 3.5 hours, then the plate was placed on agar medium seeded with B. subtilis for 10 minutes, and the TLC plate was removed finally the agar medium was incubated overnight at 37°C.
Purification and Identification of the New Antibiotic
The antibiotic products of wild-type strain, tacB disruption strain and complementary strain were isolated and purified following the protocols described previously [16, 20] .
For HPLC-ELSD analysis, the method of Hong Li-ya [21] was used, in which a reverse C 18 column (4.6 by 200 mm; 5 m m; Diamonsil, USA), mobile phase 0.2 mol/ liter TFA : MeOH (95 : 5) at a flow rate of 1.0 ml/minute was used. The drift tube temperature was 105°C, the detector was SofTA-200S (USA). High-resolution MS was performed on a Waters Quattro micro API spectrometer (USA). The NMR data was acquired on an AV-600 (600 MHz) spectrometer.
In Vitro Antibacterial Activity
The in vitro antibacterial activities were determined by agar method as described earlier [22] . The MIC was defined as the lowest concentration of antibiotic that completely inhibited visible growth of the organism.
Results and Discussion
Generation and Analysis of D DtacB Mutant S. tenebrarius tacB
؊
In order to avoid polar effects on the downstream gene transcription, an in-frame deletion was introduced into tacB. The disruption strategy was described above and illustrated in Fig. 1 .
The E. coli-Streptomyces shuttle vector pHZ132 containing DtacB (an internal SalI fragment was deleted) and erythromycin-resistant gene ermE was introduced into S. tenebrarius H6 by conjugation from E. coli ET12567 (pUZ8002). The erythromycin-resistant exconjugants were obtained. Following erythromycin-free cultivation for three rounds of sporulation, two types of double-crossover strains, namely D tacB strains and wild-type revertant strains were obtained and then identified by PCR analysis. PCR with primer 1 and 3 produced a 2.0 Kb from DtacB strains but not from wild-type revertant strains. Furthermore, this PCR amplification product from one DtacB strain was subjected to sequencing analysis with the primer S: 5Ј-TTCGGCCCCGGGTGCGC-3Ј and the result showed that only one SalI site in DtacB together with the internal 143-bp fragment was deleted. This D tacB strain was named as S. tenebrarius tacB Ϫ . The growth profile of S. tenebrarius tacB Ϫ in liquid medium CP was identical to that of the wild-type strain, while the formation of mycelia and spores was indistinguishable from that of the wild-type strain. TLC analysis of the fermentation broth showed that S.
tenebrarius tacB Ϫ produced a new component, whose Rf value was approximate to that of 3Ј-deoxycarbamoylkanamycin C [16] , as shown in Fig. 2 .
Purification and Identification of the New Antibiotic
To determine the structure of the new antibiotic produced by tacB gene disruption mutant, the antibiotic products of S. tenebrarius tacB Ϫ were isolated and purified. Positive [16] , as show in Fig. 3 .
The distinct peak at 367.2 also agrees with the mass of the sum of the DOS and 6Ј-carbamoyl-kanosamine. The result from NMR analysis further confirmed that this new antibiotic is 3Ј-deoxy-carbamoylkanamycin C [16, 23] . The 13 C-NMR data of the new antibiotic was listed in Table 2 and shown in Fig. 4 .
Complementation of the Mutant Strain S. tenebrarius tacB
؊
In order to confirm that the new antibiotic production in S. tenebrarius tacB Ϫ was due to the loss function of tacB and excluded the possibility of polar effects in the disruption mutant, restoration of the intact tacB gene in the D tacB strain, S. tenebrarius tacB Ϫ was carried out.
The complementary plasmid pSET-tacB was constructed as described above, in which the expression of the intact tacB gene is under the control of the mercury resistant promoter (Pmer) [24] . pSET-tacB was introduced into the disruption mutant S. tenebrarius tacB Ϫ by conjugation, and Ery R exconjugants were selected, named S. tenebrarius tacB Ϫ -tacB. HPLC-ELSD analysis confirmed that carbamoyltobramycin production was partially restored in S. tenebrarius tacB Ϫ -tacB in comparison with the wildtype S. tenebrarius H6 as the control, as shown in Fig. 5 . This demonstrated that the production of 3Ј-deoxycarbamoylkanamycin C in S. tenebrarius tacB Ϫ was due to a loss of tacB function.
In Vitro Activity
The antibacterial activity of 3Ј-deoxy-carbamoylkanamycin C against several bacterial is presented in Table 3 . The result showed that 3Ј-deoxy-carbamoylkanamycin C has antibacterial activity to commonly encountered and some Fig. 1 The plasmid pHZ-DtacB used in conjugation and the result of in-frame deletion of tacB via double crossover (the gray part was deleted). clinically important bacteria, although it is less active than tobramycin.
Discussion
For studying the role of the putative dehydrogenase TacB, we constructed the tacB in-frame deletion mutant S. tenebrarius tacB Ϫ . TLC bioautography showed that the mutant strain produced a new antibiotic. After isolation and purification, the structure of the new antibiotic was further determined as 3Ј-deoxy-carbamoylkanamycin C by MS and NMR analysis. The gene downstream of tacB is tacA. The intergenic region between tacB and tacA contains two palindromic sequences (GGGCCGGGCGTCGGCCCCG; CACCGGT-TCCTCACACCGGTT) that may form stem-and-loop structures in the RNA, which might act as transcription terminators of readthrough transcripts from genes upstream tacB. This may reduce the chance of polar effects or additional mutations in the disruption strain, which was demonstrated by the integration of an intact tacB gene. By performing the restoration of the intact tacB gene back into the D tacB strain, carbamoyltobramycin production was partially restored, this ruled out the possibility of a polar effect and proved that the production of 3Ј-deoxycarbamoylkanamycin C in S. tenebrarius tacB Ϫ was due to the loss of tacB function. TacB was 76% identical to the KanI in the kanamycin biosynthetic gene cluster [7] , was similar to the BtrQ (59%) in butirosin biosynthetic gene cluster [26] , ParQ (56%) in paromomycin gene cluster, and NeoG (54%) in neomycin biosynthetic gene cluster [11] . After bioinformatic analysis, 20 GSGASG 25 sequence was found in TacB. This dinucleotide binding motif of the Rossmann fold (GXGXXG) was conserved in dehydrogenases from different Streptomyces, which suggested the function of TacB as a dehydrogenase. Our result not only supported this hypothesis but also clarified the specificity of this enzyme as 6Ј-dehydrogenase in tobramycin biosynthesis. The structural difference between 3Ј-deoxycarbamoylkanamycin C and carbamoyltobramycin is that the former has a 6-hydroxyl group while the latter has a 6-amino group. The TacB is responsible for reducing the 6Ј-hydroxyl group of paromamine to a ketone group, then enabling the putative aminotransferase TacC to form neamine. Then, neamine is catalyzed to carbamoyltobramycin [4] . This is the first gene identified responsible for aminoglycoside biosynthesis after the formation of paromamine.
The new antibiotic 3Ј-deoxy-carbamoylkanamycin C is active against some common bacteria, although it is less active than tobramycin. However, the toxicity of 3Ј-deoxykanamycin C is lower than tobramycim [16, 27] .
In summary, two major outcomes have been achieved. Firstly, we identified that TacB is a 6Ј-dehydrogenase, secondly, we got a new antibiotic, 3Ј-deoxycarbamoylkanamycin C, by manipulating the biosynthesis through gene inactivation of tacB. The strategy of gene inactivation and generation of new derivatives without chemical synthesis is a promising method and a step forward to the development of new antibiotics in order to overcome problems of infections caused by multi-resistant pathogens. 
